4.4 Article

Predictability of Adjuvant Trastuzumab Benefit in N9831 Patients Using the ASCO/CAP HER2-Positivity Criteria

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Editorial Material Oncology

How Do You Tell Whether a Breast Cancer is HER2 Positive? Ongoing Studies Keep Debate in High Gear

Charlie Schmidt

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2011)

Article Medicine, General & Internal

Adjuvant Trastuzumab in HER2-Positive Breast Cancer

Dennis Slamon et al.

NEW ENGLAND JOURNAL OF MEDICINE (2011)

Article Medicine, General & Internal

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer

H Joensuu et al.

NEW ENGLAND JOURNAL OF MEDICINE (2006)

Article Medicine, General & Internal

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

MJ Piccart-Gebhart et al.

NEW ENGLAND JOURNAL OF MEDICINE (2005)

Article Medicine, General & Internal

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

EH Romond et al.

NEW ENGLAND JOURNAL OF MEDICINE (2005)

Article Oncology

Real-world performance of HER2 testing - National surgical adjuvant breast and bowel project experience

S Paik et al.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2002)

Article Oncology

Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831

PC Roche et al.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2002)

Article Medicine, General & Internal

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

DJ Slamon et al.

NEW ENGLAND JOURNAL OF MEDICINE (2001)